Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96LW7

UPID:
CAR19_HUMAN

ALTERNATIVE NAMES:
Bcl10-interacting CARD protein

ALTERNATIVE UPACC:
Q96LW7; Q5BJH8; Q9BSY2

BACKGROUND:
The protein Caspase recruitment domain-containing protein 19, with alternative names such as Bcl10-interacting CARD protein, is integral to regulating immune system responses. It achieves this by counteracting BCL10-induced NF-kappa-B activation, potentially through inhibiting BCL10 phosphorylation. This action underscores its significance in controlling signaling mechanisms that dictate immune and inflammatory reactions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Caspase recruitment domain-containing protein 19 holds promise for unveiling new therapeutic avenues. Given its pivotal role in immune regulation, strategies aimed at modulating its activity could lead to innovative treatments for managing immune-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.